Atherosclerosis
Volume 191, Issue 1 , Pages 54-62 , March 2007

Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses

  • Yi Shi

      Affiliations

    • Thomas Jefferson University, Philadelphia, PA, United States
    • Corresponding Author InformationCorrespondence to: Department of Surgery, Thomas Jefferson University, Suite 623, 1025 Walnut Street, Philadelphia, PA 19107, United States. Tel.: +1 215 955 2693; fax: +1 215 955 2878.
    • ,
  • Ping Zhang

      Affiliations

    • Thomas Jefferson University, Philadelphia, PA, United States
    • ,
  • LiFeng Zhang

      Affiliations

    • Thomas Jefferson University, Philadelphia, PA, United States
    • ,
  • Hashim Osman

      Affiliations

    • University of Pennsylvania, Philadelphia, PA, United States
    • ,
  • Emile R. Mohler III

      Affiliations

    • University of Pennsylvania, Philadelphia, PA, United States
    • ,
  • Colin Macphee

      Affiliations

    • GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, United States
    • ,
  • Andrew Zalewski

      Affiliations

    • Thomas Jefferson University, Philadelphia, PA, United States
    • GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, United States
    • ,
  • Anthony Postle

      Affiliations

    • University of Southampton, UK
    • ,
  • Robert L. Wilensky

      Affiliations

    • University of Pennsylvania, Philadelphia, PA, United States

Received 21 November 2005 ,Revised 4 April 2006 ,Accepted 1 May 2006.

Reference 

  1. Six DA, Dennis EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta. 2000;1488:1–19
  2. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis—biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923–931
  3. West of Scotland Coronary Prevention Study GroupPackard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148–1155
  4. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–1306
  5. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903–1908
  6. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation. 2004;109:837–842
  7. Oei H-HS, van der Meer I, Hofman A, et al. Lipoprotein-associated phospholipase A2 is associated with risk of coronary heart disease and stroke: the Rotterdam study. Circulation. 2005;111:570–575
  8. Ballantyne C, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities study. Circulation. 2004;110:III–641
  9. Iribarren C, Gross MD, Darbinian JA, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol. 2005;25:216–221
  10. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen risk and cardiovascular health study. Circulation. 2005;111:980–987
  11. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479–487
  12. Marathe GK, Harrison KA, Murphy RC, et al. Bioactive phospholipid oxidation products. Free Radic Biol Med. 2000;28:1762–1770
  13. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995;374:549–553
  14. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem. 1997;272:17895–17898
  15. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003;14:421–430
  16. Brochériou I, Stengel D, Mattsson-Hultén L, et al. Expression of platelet-activating factor receptor in human carotid atherosclerotic plaques relevance to progression of atherosclerosis. Circulation. 2000;102:2569–2575
  17. Benitez S, Sanchez-Quesada JL, Ribas V, et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation. 2003;108:92–96
  18. Zhang L, Zalewski A, Liu Y, et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation. 2003;108:472–478
  19. Liebisch G, Drobnik W, Lieser B, Schmitz G. High-throughput quantification of lysophosphatidylcholine by electrospray ionization tandem mass spectrometry. Clin Chem. 2002;48:2217–2224
  20. Mazurek T, Zhang LF, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460–2466
  21. Waehre T, Damas JK, Gullestad L, et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol. 2003;41:1460–1467
  22. Waehre T, Yndestad A, Smith C, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation. 2004;109:1966–1972
  23. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12
  24. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999;261:511–514
  25. Stafforini DM, Tjoelker LW, McCormick SP, et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999;274:7018–7024
  26. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:2495–2500
  27. Carpenter K, Dennis I, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2, diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357–363
  28. Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000;102:2180–2184
  29. Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266–1271
  30. Kujiraoka T, Iwasaki T, Ishihara M, et al. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. J Lipid Res. 2003;44:2006–2014
  31. Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem. 1989;264:8467–8470
  32. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of Inflammation. J Biol Chem. 1998;273:4012–4020
  33. Watanabe J, Marathe GK, Neilsen PO, et al. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J Biol Chem. 2003;278:33161–33168
  34. Wu X, Zimmerman GA, Prescott SM, Stafforini DM. The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem. 2004;279:36158–36165
  35. Yamakawa T, Tanaka S, Yamakawa Y, et al. Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2002;22:752–758
  36. Takahashi M, Okazaki H, Ogata Y, et al. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis. 2002;161:387–394
  37. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–1960
  38. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649–1654
  39. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909–2917
  40. Kolodgie F, Burke A, Taye A, et al. Lipoprotein-associated phospholipase A2 is highly expressed in macrophages of coronary lesions prone to rupture. Circulation. 2004;110:III–246
  41. Johnson A, Zalewski A, Janmohamed S, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study (Abstr. 2745). Circulation. 2004;110:III–590

PII: S0021-9150(06)00251-6

doi: 10.1016/j.atherosclerosis.2006.05.001

Atherosclerosis
Volume 191, Issue 1 , Pages 54-62 , March 2007

Article Tools

* Image Usage & Resolution